The $1.5 million award will help translate cutting-edge nanoparticle immunotherapy approach to the clinic
Oct. 30, 2018
| By Sabrina Richards / Fred Hutch News Service
Fred Hutch immunobioengineer Dr. Matthias Stephan, who is developing the use of immune-cell-programming nanoparticles as a cancer treatment, has been named a 2018 Allen Distinguished Investigator by The Paul G. Allen Frontiers Group.
The honor will support Lee in perpetuity as she continues her research on blood stem cell transplantation and chronic GVHD
Oct. 17, 2018
| By Diane Mapes / Fred Hutch News Service
Fred Hutch physician-scientist Dr. Stephanie Lee, the second recipient of the David and Patricia Giuliani/Oliver Press Endowed Chair in Cancer Research, was honored at an Oct. 12 ceremony at Fred Hutch.
Large clinical trial funded by $3.5M federal research grant
Oct. 5, 2018
| By Susan Keown / Fred Hutch News Service
Dr. Mohamed Sorror has received a new five-year, $3.5 million grant from the National Cancer Institute to conduct a large clinical trial aimed at improving the quality of life and survival of medically vulnerable patients after they receive a transplant of donated blood-forming stem cells.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.